Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Hypotension 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 5Gemcitabine 3Nivolumab 2Injections 2E 7107 2Docetaxel 2Carboplatin 2Antibodies, Monoclonal 2130-nm albumin-bound paclitaxel 2venetoclax 1trastuzumab biosimilar HLX02 1taxane 1spartalizumab 1resiniferatoxin 1poly(I).poly(c12,U) 1pegamotecan 1palbociclib 1lenvatinib 1imisopasem manganese 1icotinib 1gusacitinib 1famitinib 1eniluracil 1dabrafenib 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1cobimetinib 1brincidofovir 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1abivertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × imisopasem manganese × Clear all
NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

MetaPhore Pharmaceuticals

Phase 1/2 Suspended
48 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡